Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William G Kramer

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology in Drug Development|November 15, 2017
Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian AdultsWilliam G Kramer, Michal Jaron-Mendelson, Ronit Koren, et al.
Clinical Pharmacology : Advances and Applications|October 28, 2016
Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteersNeha Parikh, William G Kramer, Varun Khurana, et al.
Journal of Clinical Pharmacology|April 9, 2015
Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonistBrian W Ogilvie, Rosarelis Torres, Marlene A Dressman, et al.
Antimicrobial Agents and Chemotherapy|May 17, 2024
Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participantsMichael R Hodges, Sjoerd van Marle, William G Kramer, et al.
Journal of Clinical Pharmacology|October 21, 2010
Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjectsMichael E Bozik, James L Mather, William G Kramer, et al.
European Journal of Clinical Pharmacology|March 31, 2012
A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteersKarthik Venkatakrishnan, William G Kramer, Timothy W Synold, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 12, 2003
Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteersHarumi Kitagawa, Toshiharu Takenouchi, Ryotaro Azuma, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2024
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participantsMichael R Hodges, Susan Hazel, William G Kramer, et al.
Clinical Therapeutics|March 9, 2010
Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adultsDonald G Musson, William G Kramer, Erik D Foehr, et al.
The Journal of Antimicrobial Chemotherapy|September 8, 2023
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropeniaOliver A Cornely, Helmut Ostermann, Philipp Koehler, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology in Drug Development|November 15, 2017
Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian AdultsWilliam G Kramer, Michal Jaron-Mendelson, Ronit Koren, et al.
Clinical Pharmacology : Advances and Applications|October 28, 2016
Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteersNeha Parikh, William G Kramer, Varun Khurana, et al.
Journal of Clinical Pharmacology|April 9, 2015
Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonistBrian W Ogilvie, Rosarelis Torres, Marlene A Dressman, et al.
Antimicrobial Agents and Chemotherapy|May 17, 2024
Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participantsMichael R Hodges, Sjoerd van Marle, William G Kramer, et al.
Journal of Clinical Pharmacology|October 21, 2010
Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjectsMichael E Bozik, James L Mather, William G Kramer, et al.
European Journal of Clinical Pharmacology|March 31, 2012
A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteersKarthik Venkatakrishnan, William G Kramer, Timothy W Synold, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|March 12, 2003
Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteersHarumi Kitagawa, Toshiharu Takenouchi, Ryotaro Azuma, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2024
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participantsMichael R Hodges, Susan Hazel, William G Kramer, et al.
Clinical Therapeutics|March 9, 2010
Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adultsDonald G Musson, William G Kramer, Erik D Foehr, et al.
The Journal of Antimicrobial Chemotherapy|September 8, 2023
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropeniaOliver A Cornely, Helmut Ostermann, Philipp Koehler, et al.
Pageof 4